Dr. Reddy's Laboratories Limited (RDY) News
Follow Dr. Reddy's Laboratories Limited (RDY) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 20 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
H
Dr Reddy's Laboratories Q1 2027 Earnings Call Transcript
Dr Reddy's Laboratories (NYSE: RDY ) held its first-quarter earnings conference call on Wednesday. Below is the complete transcript from the call. This content is powered APIs. For comprehensive financial data and transc
LIVE | Sep 17, 2026, 07:42 AM UTC
L
ReadyTech target price raised to A$2.25 by Morgans
Morgans raised its ReadyTech target price by 4.7% to A$2.25 per share for RDY.AU.
EQUITY | Aug 31, 2026, 11:38 PM UTC
L
ReadyTech price target raised to A$1.55 by Canaccord Genuity
Canaccord Genuity raised its ReadyTech price target by 16% to A$1.55 per share.
EQUITY | Aug 27, 2026, 11:32 PM UTC
L
RDY: AI transformation, cost discipline, and strategic wins position for margin recovery in FY 2027
RDY: AI transformation, cost discipline, and strategic wins position for margin recovery in FY 2027
EQUITY | Aug 27, 2026, 02:09 AM UTC
L
RDY: cost discipline and AI adoption support growth outlook
RDY cites cost discipline, AI adoption, and enterprise wins as positioning for margin and revenue growth ahead.
EARNINGS | Aug 27, 2026, 01:37 AM UTC
M
RDY reports FY26 modest revenue growth amid margin pressure
RDY’s FY26 delivered modest revenue growth, margin pressure, and strong AI-driven operational gains.
EQUITY | Aug 27, 2026, 12:14 AM UTC
L
RDY: Flagship growth and AI gains offset churn, with FY27 guidance targeting margin recovery
RDY: Flagship growth and AI gains offset churn, with FY27 guidance targeting margin recovery
EARNINGS | Aug 26, 2026, 10:35 PM UTC
L
RDY revenue up; losses narrowed; recurring strong, margins pressured
RDY reported revenue growth and narrowed losses, with strong recurring revenue. Margins were pressured and growth was expected.
EQUITY | Aug 26, 2026, 10:28 PM UTC
L
ReadyTech will not pay a final dividend
ReadyTech says it will not pay a final dividend.
EQUITY | Aug 26, 2026, 10:06 PM UTC
L
ReadyTech FY revenue A$125.0 million, up 2.6%
ReadyTech reported FY revenue of A$125.0 million, up 2.6%.
EQUITY | Aug 26, 2026, 10:05 PM UTC
M
ReadyTech FY net loss A$4.9 million, down 70%
ReadyTech reported FY net loss of A$4.9 million, down 70%.
EQUITY | Aug 26, 2026, 10:05 PM UTC
H
India's Dr Reddy's receives FDA Form 483
Dr Reddy's gets FDA Form 483 with three observations
REGULATION | Jul 29, 2026, 04:15 PM UTC
L
RDY Dr reddy's exec - been good traction for our Semaglutide product in market - Do not see any concerns on stock, inventory - Overall india
RDY Dr reddy's exec - been good traction for our Semaglutide product in market - Do not see any concerns on stock, inventory - Overall indian market will continue to grow double-digit
EQUITY | Jul 22, 2026, 12:40 PM UTC
L
RDY Dr reddy's exec on Semaglutide- we understood chemistry and rootcause, results are expected in September Dr reddy's exec on Semaglutide
RDY Dr reddy's exec on Semaglutide- we understood chemistry and rootcause, results are expected in September Dr reddy's exec on Semaglutide- hopefully will get Semaglutide to market by November
EQUITY | Jul 22, 2026, 12:27 PM UTC
H
RDY Dr reddy's exec on tariff - not going to do anything special immediately due to tariff announcement, will assess
RDY Dr reddy's exec on tariff - not going to do anything special immediately due to tariff announcement, will assess
GEOPOLITICS | Jul 22, 2026, 12:27 PM UTC
H
RDY Dr reddy's exec on tariff - if tariff is imposed, will raise prices in the U.S.
RDY Dr reddy's exec on tariff - if tariff is imposed, will raise prices in the U.S.
GEOPOLITICS | Jul 22, 2026, 12:27 PM UTC
H
RDY Dr reddy's exec on tariff- been in these cycles before, not practical to move to U.S. immediately
RDY Dr reddy's exec on tariff- been in these cycles before, not practical to move to U.S. immediately
GEOPOLITICS | Jul 22, 2026, 12:26 PM UTC
L
RDY Dr reddy's exec- elevated frieght costs due to middle East issues, high solvent prices impacted EBITDA this qtr Dr reddy's exec- launche
RDY Dr reddy's exec- elevated frieght costs due to middle East issues, high solvent prices impacted EBITDA this qtr Dr reddy's exec- launched generic Semaglutide tablets in India Dr reddy's exec- working to resume Semagl
EQUITY | Jul 22, 2026, 12:20 PM UTC
L
RDY Dr. Reddy's RESULTS: Q1, Q1 consol total REV from ops 81B rupees; consensus est. 81.6B rupees, Q1 consol net Pat 4.44B rupees; consensus
RDY Dr. Reddy's RESULTS: Q1, Q1 consol total REV from ops 81B rupees; consensus est. 81.6B rupees, Q1 consol net Pat 4.44B rupees; consensus est. 7.22B rupees
EQUITY | Jul 22, 2026, 11:19 AM UTC
H
Full Transcript: Dr Reddy's Laboratories Q4 2026 Earnings Call
Dr Reddy's Laboratories (NYSE: RDY ) released fourth-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. APIs provide real-time access to earnings call transcripts and fi
EARNINGS | Jul 01, 2026, 08:20 AM UTC